Dabrafenib with Trametinib with adjuvant therapy for treating advanced BRAF V600 mutation-positive melanoma in adolescents

Dabrafenib in combination with trametinib is currently in clinical development for the treatment of advanced BRAF V600 mutation-positive melanoma in adolescents. Melanoma is a type of skin cancer. Common signs include the appearance of a new mole or a change in an existing mole. This can happen anywhere on the body, but the most commonly affected areas are the back in men and the legs in women. It is caused by ultraviolet (UV) light damaging the DNA in skin cells. Despite being rare, melanoma is the most common cancer in children, and is more common in adolescents aged 15 – 19 years. Adjuvant therapy is a therapy that is given in addition to the primary or initial therapy to maximise its effectiveness. Current treatment options are limited and often include surgical interventions. Adjuvant therapy options are crucial because more than half of patients have a recurrence after surgery.